Media.Player

Obesity treatment with a satiety promoting peptide

總結

Paul David Berk, M.D.

技術優勢

This peptide is a natural hormone peptide. Already has natural biological activity in the gut and in significantly under-expressed in obese patients. Successfully reduces body weight by reducing food intake, eliminating adipocyte free fatty acid uptake rates in several models of obesity, including tissue samples from obese humans.Patent information:(WO2012051567)Tech Ventures Reference: IR 2723

技術應用

Treatment of obesity, general weight control and appetite regulationTreatment of metabolic syndrome, insulin resistance, fatty liver disease, obesity related cardiomyopathy and other obesity-associated disorders. Detection of obesity or obesity-associated disordersDetection of an obesity classification based on message or protein expression profilingAn alternative treatment and/or complement to obesity surgery

詳細技術說明

Paul David Berk, M.D.

*Abstract

None

*Inquiry

Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

2723

*Principal Investigation

*Publications

*Walewski, JL et al. Spexin is a novel human peptide that reduces adipocyte uptake of long chain fatty acids and causes weight loss in rodents with diet-induced obesity. Obesity (Silver Spring). Feb, 2014.

國家/地區

美國